Observational study: prospective longitudinal cohort (Green)
Authors: Carl H Göbel, Axel Heinze, Sarah Karstedt, Mascha Morscheck, Lilian Tashiro, Anna Cirkel, Qutayba Hamid, Rabih Halwani, Mohamad-Hani Temsah, Malte Ziemann, Siegfried Görg, Thomas Münte, Hartmut Göbel
The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed COVID-19 vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated. Detailed information about the clinical characteristics of this form of headache has not yet been described. Göbel et al. studied patients who suffered headaches after their COVID-19 vaccination with the BioNTech/Pfizer mRNA or ChAdOx1 nCoV-19 (AZD1222) vaccine. The headaches showed an extensive complex of symptoms. The constellation of accompanying symptoms together with the temporal and spatial headache characteristics delimit a distinctive phenotype that allows differentiation from other headache forms.
Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study, DOI: https://doi.org/10.1093/braincomms/fcab169
Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study, DOI: https://doi.org/10.1007/s40122-021-00296-3